Glenmark Pharmaceuticals Limited (BOM:532296)
2,066.95
-66.25 (-3.11%)
At close: Aug 1, 2025
Model N Revenue
In the fiscal year ending March 31, 2025, Glenmark Pharmaceuticals had annual revenue of 134.35B INR with 6.25% growth. Glenmark Pharmaceuticals had revenue of 32.68B in the quarter ending March 31, 2025, a decrease of -16.11%.
Revenue
134.35B
Revenue Growth
+6.25%
P/S Ratio
4.34
Revenue / Employee
8.96M
Employees
14,989
Market Cap
583.53B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 134.35B | 7.90B | 6.25% |
Mar 31, 2024 | 126.45B | 9.90B | 8.49% |
Mar 31, 2023 | 116.56B | -6.49B | -5.28% |
Mar 31, 2022 | 123.05B | 13.61B | 12.44% |
Mar 31, 2021 | 109.44B | 2.87B | 2.69% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,765.41B |
HDFC Bank | 2,736.06B |
Bharti Airtel | 1,729.85B |
Tata Consultancy Services | 2,561.48B |
ICICI Bank | 2,054.85B |
State Bank of India | 3,429.39B |
Infosys | 1,672.76B |
Hindustan Unilever | 639.28B |
Glenmark Pharmaceuticals News
- 17 days ago - Nomura remains neutral on Glenmark, says near-term upside for stock captured post ISB-2001 deal - Business Upturn
- 20 days ago - Top stocks to buy: Stock recommendations for the week starting July 14, 2025 - check list - The Times of India
- 20 days ago - Top stocks in focus on July 14; DMart, Glenmark Pharma, VIP Industries, NCC, RITES, Ajmera Realty and more - Business Upturn
- 20 days ago - HSBC raises Glenmark Pharma share price target to Rs 2,275 on $1.9 billion AbbVie licensing deal - Business Upturn
- 21 days ago - Glenmark Pharma receives warning letter from US FDA for Indore facility - Business Upturn
- 23 days ago - Glenmark Pharma shares surge 10% after its subsidiary signs $700 million licensing deal with AbbVie for ISB 2001 - Business Upturn
- 23 days ago - Top stocks in focus on July 11: Tata Steel, TCS, Tata Elxsi, Glenmark Pharma, HUL, JSW Infrastructure and more - Business Upturn
- 23 days ago - Glenmark shares in focus after $700 million AbbVie deal for ISB 2001 - Business Upturn